Pulmonary embolism: what does the new AHA/ACC 2026 guide add.

Recently, the 2026 American Heart Association (AHA)/American College of Cardiology (ACC)/American College of Chest Physicians/American College of Chest Physicians/Society for Cardiovascular Angiography and Interventions/Society of Hospital Medicine/Society of Interventional Radiology/Society of Vascular Medicine/Society for Vascular Nursing Guideline for Evaluation and Management of Acute Pulmonary Embolism in Adults (AHA/ACC Acute PE Guideline) has been published. We aimed to critically evaluate the most significant sections of the guidelines. The new risk classification provides granularity, although the new categories require validation. We concur with the guidelines' recommendations regarding the use of low-molecular-weight heparins (parenteral treatment) and direct oral anticoagulants (oral treatment) as the preferred anticoagulants for the vast majority of patients with acute PE. Finally, the guidelines suggest reperfusion therapies for scenarios that currently lack robust scientific evidence; therefore, the results of ongoing clinical trials must be awaited to determine their precise indications.